Investors

Rights Issue 2020

On 24 November 2020, Scandion Oncology A/S published a prospectus and initiated a rights issue. The rights trading period will be from 26 November to 10 December 2020. Expectedly, the publication of result of the Offering will be announced on 15 December 2020. Below you can find various material related to the Offering.

Prospectus
Supplementary document
Press release 24 November 2020
Teaser
Company presentation
Certificate of Registration, Danish Business Authority
Subscription form

FAQ

Please contact your bank/custodian for instructions how to subscribe with subscription rights.

For subscription of new shares without subscription rights, please use the Application form for subscription of shares in Scandion Oncology A/S – without subscription rights, which is made available on Scandion Oncology’s website.

If you are a direct registered shareholder, you will receive a pre-printed issue statement together with a payment form in your mail. You may use the payment form to subscribe new shares.

If you are a nominee registered shareholder, please contact your nominee bank for further instructions.

Hagberg & Aneborn Fondkommision AB
Matter: Scandion Oncology
Valhallavägen 124
SE-114 41 Stockholm

Tel: +46 8 408 933 50
Fax: +46 8 408 933 51
Email: info@hagberganeborn.se (scanned subscription forms)

Preliminary timetable for the Rights Issue

20 November 2020
Last trading day in Scandion Oncology’s shares including the right to receive subscription rights in the Rights Issue

23 November 2020
First trading day in Scandion Oncology’s shares excluding the right to receive subscription rights in the Rights Issue

24 November 2020
The record date for the Rights Issue

26 November – 10 December 2020
Subscription period of the Rights Issue

26 November – 8 December 2020
Trading in subscription rights on Spotlight Stock Market

26 November – Until conversion of BTAs to new shares
Trading in BTAs ongoing until the Danish Business Authority has registered the Rights Issue and BTAs are converted to shares

Around 15 December 2020
The expected date for the announcement of the outcome in the Rights Issue

Around 11 January 2021
Trading in new shares commences